“Sloppy” Searle Studies Described By FDA At Kennedy Hearing; Rauscher “Outraged”
In Brief: Override Failure Would Leave Cancer Program With No Money or New Projects Of Any Kind
NCI Budget for FY 1977 Would Halt New Research
Congressman Obey Attacks NCI for Not Supporting Basic Research
Nutrition RFPs Will Really Be Grants, Gori Says
Cyclamate Committee Finds No Proof Of Carcinogenicity
Trending Stories
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home









